Table of Contents Table of Contents
Previous Page  15 / 34 Next Page
Information
Show Menu
Previous Page 15 / 34 Next Page
Page Background

Treatment options in 2

nd

-3

rd

line

AXITINIB

NIVOLUMAB

CABOZANTINIB

LENVATINIB +

EVEROLIMUS

Choueiri et al Lancet Oncol 2016